Development of Preclinical Models to Understand and Treat Colorectal Cancer

Area of Science:

• Oncology
• Translational Research
• Cancer Biology

Background:

• Preclinical models are essential for understanding colorectal cancer (CRC) pathogenesis and treatment responses.
• Advances in precision medicine for metastatic CRC require knowledge of molecular determinants of therapy response.
• Existing models have been instrumental in elucidating molecular drivers of colorectal tumor progression.

Purpose of the Study:

• To review and compare the merits and limitations of various in vitro and in vivo preclinical models for colorectal cancer research.
• To highlight the importance of these models in understanding CRC pathogenesis and therapeutic responses.
• To inform the selection of appropriate models for studying CRC and evaluating experimental therapies.

Main Methods:

• Comparative review of existing literature on in vitro and in vivo preclinical models for colorectal cancer.
• Analysis of the strengths and weaknesses of different model systems.
• Discussion of model relevance to human CRC pathogenesis and treatment response.

Main Results:

• A broad spectrum of in vitro and in vivo models exists for colorectal cancer research.
• Each model type possesses unique advantages and disadvantages regarding recapitulating CRC.
• Understanding model limitations is key to interpreting experimental results and their clinical applicability.

Conclusions:

• The choice of preclinical model significantly impacts the study of colorectal cancer and the development of new therapies.
• Validated models are critical for advancing precision medicine in CRC by identifying molecular predictors of treatment success.
• Continued development and critical evaluation of preclinical models are necessary for therapeutic innovation in colorectal cancer.